Clearmind net loss narrows to USD 907,291 in Q3 FY26; cash climbs to USD 12.04 million at July 31, 2026
CMND•Cash position improves, nine-month loss widens
Cash and cash equivalents rose to USD 12.04 million at July 31, 2026 from USD 3.92 million at Oct. 31, 2025.
Nine-month net loss widened to USD 6.81 million from USD 3.17 million, while net cash used in operations increased to USD 5.78 million.
Q3 net loss narrows while operating expenses rise
Clearmind Medicine reported a net loss of USD 907,291 for the three months ended July 31, 2026, narrowing 30.95% year over year.
Loss per share improved to USD 0.57 from USD 96.73 a year earlier, reflecting the reverse share splits.
Total operating expenses climbed 54.84% to USD 2.18 million, led by general and administrative costs rising to USD 1.59 million.
